Navigation Links
InVitria Further Strengthens Sales Team with Promotion of Brandy Sargent to Account Manager - Western United States

FORT COLLINS, Colo., Sept. 3 /PRNewswire/ -- InVitria (, a leading global supplier of animal free products that enhance productivity, safety and time to market for companies in the biopharmaceutical, cell culture, life science research and diagnostics industry, today announced the promotion of Brandy Sargent to Account Manager for the Western United States.

"Brandy has played a vital role in the development and growth of the InVitria's business through her previous roles with the company and we expect her to have an even bigger impact in her new position as Account Manager," said InVitria president Scott Deeter.

Brandy has been with InVitria since 2001, serving in a variety of capacities, including corporate communications and marketing. In her new role, she will work with customer accounts within the biopharmaceutical, cell culture and diagnostics industry located in the Western United States.

"I am very excited about my latest opportunity with InVitria," said Brandy Sargent. "InVitria's animal free product line offers customers a safe, cost-effective way to improve their bioprocessing productivity and product yield. The customer response to our products has been terrific and I am delighted to be working closely with our customers as part of the front-line sales team," said Brandy.

In several studies, InVitria's Cellastim -- a recombinant albumin developed specifically as a cell culture ingredient -- enhances cell growth and productivity better than plasma-derived albumin. Cellastim can supplement chemically defined media as well as traditional media. It has been successfully utilized in CHO, Hybridoma, NSO, Keratinocyte, Fibroblast and primary cell media.

To learn more about InVitria's animal free products, including its recombinant albumin, please email

About InVitria (

InVitria has developed animal free cell culture ingredients that enhance productivity, safety and time to market for companies in the biopharmaceutical, cell culture, life science research and diagnostics industry. InVitria's animal free product line includes:

-- Cellastim - Cellastim is an albumin used to replace bovine albumin and human albumin as a cell culture ingredient and biopharmaceutical formulation excipient. Cellastim has been shown to improve mammalian cell culture productivity by up to 50% when compared with other forms of albumin. Cellastim also has been an effective component in stem cell media and primary cell media.

-- Lacromin - Lacromin has been shown to replace bovine transferrin and human transferrin in cell culture media. In addition, Lacromin is a strong growth promotant as a cell culture ingredient in mammalian cell culture media.

-- Lysobac - Lysobac is a bacterial cell lysis agent that is more efficient and more consistent compared to chicken lysozyme and provides higher protein yield compared with mechanical cell lysis. Lysobac is used in bacterial fermentation to improve recombinant protein yields.

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. InVitrias Animal Free Lacromin(TM) Provides a Cost-Effective Improvement Over Transferrin
2. InVitria Expands Sales Team
3. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
4. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
5. VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives
6. Adds Mobile Phone Capability Further Speeding Access to Experienced Monitors
7. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
8. Organons Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder
9. Agencourt Genomic Services is Key Collaborator in New Research That Further Defines Landscape of Breast and Colon Cancers
10. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
11. SAFC Hitech(TM) Plans Further Expansion Into Asia
Post Your Comments:
(Date:11/24/2015)... SAN DIEGO , Nov. 24, 2015 Halozyme Therapeutics, ... Jaffray Healthcare Conference in New York on ... Dr. Helen Torley , president and CEO, will provide a ... New York at 1:00 p.m. ET/10:00 a.m. ... communication and investor relations, will provide a corporate overview. --> ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... healthy metabolism. But unless it is bound to proteins, copper is also toxic ... (NIH), researchers at Worcester Polytechnic Institute (WPI) will conduct a systematic study of ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... IIROC on behalf of the Toronto Stock Exchange, confirms ... there are no corporate developments that would cause the ... --> --> About Aeterna Zentaris ... . --> Aeterna Zentaris is a specialty ...
(Date:11/24/2015)... PUNE, India , November 24, 2015 ... to a new market research report "Oligonucleotide Synthesis Market ... Equipment), Application (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User ... to 2020", published by MarketsandMarkets, the market is expected ... 1,078.1 Million in 2015, at a CAGR of 10.1% ...
Breaking Biology Technology:
(Date:11/17/2015)... , November 17, 2015 ... 19 novembre  2015.  --> Paris , ... --> DERMALOG, le leader de l,innovation biométrique, a ... fois passeports et empreintes sur la même surface de ... passeports et l,autre pour les empreintes digitales. Désormais, un ...
(Date:11/12/2015)... Nov. 12, 2015  A golden retriever that stayed ... dystrophy (DMD) has provided a new lead for treating ... the Broad Institute of MIT and Harvard and the ... . Cell, pinpoints a protective ... the disease,s effects. The Boston Children,s lab of ...
(Date:11/10/2015)... , Nov. 10, 2015  In this ... the basis of product, type, application, disease ... in this report are consumables, services, software. ... are safety biomarkers, efficacy biomarkers, and validation ... report are diagnostics development, drug discovery and ...
Breaking Biology News(10 mins):